肾素-血管紧张素系统抑制剂对2型糖尿病下呼吸道感染的影响:Fremantle糖尿病研究II期
Fremantle糖尿病研究II期纳入1482例确诊2型糖尿病患者,随访至2016年底,评估基线使用ACEI/ARB与肺炎/流感住院或死亡的关系。Cox回归显示基线ACEI/ARB使用与肺炎/流感风险降低独立相关(原因特异性HR 0.64,95%CI 0.45-0.89,P=0.008),竞争风险分析结果一致(亚分布HR 0.67,95%CI 0.48-0.95,P=0.024)。
要点
- 基线ACEI/ARB使用与2型糖尿病患者肺炎/流感风险降低独立相关(原因特异性HR 0.64,95%CI 0.45-0.89)。
- 考虑死亡竞争风险后结果一致(亚分布HR 0.67,95%CI 0.48-0.95,P=0.024)。
- ACEI单用、ARB单用及ACEI/ARB联合治疗均可见相似的风险降低。
核心结论
- ACEI/ARB可降低2型糖尿病患者肺炎/流感风险。
研究设计与样本
- 纵向观察性Fremantle糖尿病研究II期(FDS2)于2008至2011年招募1732例糖尿病患者,其中1482例确诊2型糖尿病(平均年龄65.8岁,糖尿病病程中位数9.0年,51.6%为男性)。
- 随访至2016年底,通过验证的行政数据链接确定因肺炎/流感住院或死亡,采用Cox回归和竞争风险回归分析独立预测因素。
主要发现
- 随访期间共9511人年(平均±SD 6.4±2.0年),174例发生肺炎/流感(156例住院,18例未住院死亡)。
- 基线ACEI/ARB使用与肺炎/流感风险降低独立相关(原因特异性HR 0.64,95%CI 0.45-0.89,P=0.008)。
- 考虑死亡竞争风险后结果不变(亚分布HR 0.67,95%CI 0.48-0.95,P=0.024),ACEI单用、ARB单用及联合治疗均见相似降低。
- 随访期间ACEI/ARB使用无显著变化(与ln(time)交互作用P=0.70)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) protect against lower-respiratory tract infections complicating type 2 diabetes. RESEARCH DESIGN AND METHODS: Of 1,732 participants with diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011, 1,482 had confirmed type 2 diabetes (mean age 65.8 years and median diabetes duration 9.0 years; 51.6% were male). All were followed for hospitalizations for or with, or deaths from, pneumonia/influenza, ascertained from validated administrative data linkage from study entry to end of 2016. Cox regression and competing risk regression were used to identify independent predictors of this outcome. RESULTS: Two-thirds of participants (n = 982) were taking an ACEi and/or ARB at study entry (498 [33.6%] ACEi, 408 [27.5%] ARB, 76 [5.1%] both). During 9,511 person-years of follow-up (mean ± SD 6.4 ± 2.0 years), 174 participants had incident pneumonia/influenza (156 hospitalizations and 18 deaths without hospitalization). In Cox regression analysis, baseline ACEi/ARB use was independently associated with a reduced risk of incident pneumonia/influenza (cause-specific hazard ratio [HR] 0.64 [95% CI 0.45, 0.89], P = 0.008). Allowing for the competing risk of death did not change this finding (subdistribution HR 0.67 [0.48, 0.95], P = 0.024), and similar reductions were seen for ACEi, ARB alone, and ACEi/ARB combination therapy. There was no significant change in use of ACEi/ARB during follow-up [interaction with ln(time), P = 0.70]. Other significant predictors of incident pneumonia/influenza were previously reported, clinically plausible variables. CONCLUSIONS: ACEi/ARB reduce the risk of pneumonia/influenza in people with type 2 diabetes.
引用
- Davis TME, Davis WA. Influence of Renin-Angiotensin System Inhibitors on Lower-Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care. 2020. PMID: 32616610. doi:10.2337/dc20-0895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。